Pembrolizumab Plus GX-188E Therapeutic DNA Vaccine in Patients With HPV-16–Positive or HPV-18–Positive Advanced Cervical Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus GX-188E Therapeutic DNA Vaccine in Patients With HPV-16-Positive or HPV-18-Positive Advanced Cervical Cancer: Interim Results of a Single-Arm, Phase 2 Trial
Lancet Oncol 2020 Dec 01;21(12)1653-1660, JW Youn, SY Hur, JW Woo, YM Kim, MC Lim, SY Park, SS Seo, JH No, BG Kim, JK Lee, SJ Shin, K Kim, MF Chaney, YJ Choi, YS Suh, JS Park, YC SungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.